121 signals · bluesky, News / RSS, Yahoo Finance
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Moderate risk indicators present across data sources.
Auto-generated from public signals — AI summary pending. Based on 3 recent signals.
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher Yahoo Finance
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength CNBC Merck Earnings Blow Past Estimates. Why Wall Street Has Its Eyes on the Coming Year. Barron's Merck to boost next decade revenue forecast on new drugs optimism Reuters Merck Revenue Up on Keytruda, Winrevair Growth WSJ Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher Yahoo Finance Dear Merck Stock Fans, Mark Your Calendars for October 29 Barchart.
Barron's Merck to boost next decade revenue forecast on new drugs optimism Reuters Merck Revenue Up on Keytruda, Winrevair Growth WSJ Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher Yahoo Finance Dear Merck Stock Fans, Mark Your Calendars for October 29 Barchart.
Medical devices, pharmaceuticals, and consumer health.
Based on 121 signals across 3 sources · snapshot 4 Nov 2026
Strong: enough recent evidence to trust this score.
Overall community sentiment for Johnson & Johnson is mixed based on public signals as of 4 Nov 2026.
Based on 121 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
Law firm investigates Johnson & Johnson over Q3 earnings and revenue miss amid talc litigation costs. Pluang
Law firm investigates Johnson & Johnson over Q3 earnings and revenue miss amid talc litigation costs.